Company profile

Ticker
VRML
Exchange
CEO
Valerie Barber Palmieri
Employees
Incorporated in
Location
Fiscal year end
Former names
Ciphergen Biosystems Inc
SEC CIK
IRS number
330595156

VRML stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 Nov 19
6 Apr 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 1.29M 1.14M 803K 922K
Net income -3.82M -4.31M -3.72M -2.82M
Diluted EPS -0.04 -0.06 -0.05 -0.03
Net profit margin -297% -378% -463% -306%
Operating income -3.85M -4.31M -3.72M -2.82M
Net change in cash -1.54M 10.01M -3.19M -2.4M
Cash on hand 14.64M 16.18M 6.17M 9.36M
Cost of revenue 949K 908K 694K 753K
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 3.05M 3.12M 2.64M 2.18M
Net income -11.37M -10.5M -14.97M -19.12M
Diluted EPS -0.16 -0.2 -0.29 -0.41
Net profit margin -372% -336% -567% -878%
Operating income -11.33M -10.44M -14.95M -19.25M
Net change in cash 3.82M 297K -13.4M -4.32M
Cash on hand 9.36M 5.54M 5.24M 18.64M
Cost of revenue 3.14M 2.91M 2.7M 2.31M

Financial data from Vermillion earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
19 Mar 20 Burns James S Common Stock Grant Aquire A 0 65,156 0 462,211
19 Mar 20 Burns James S Employee Stock Option Common Stock Grant Aquire A 0.68 113,300 77.04K 113,300
19 Mar 20 Lafrance James T Common Stock Grant Aquire A 0 84,986 0 429,459
19 Mar 20 Lafrance James T Employee Stock Option Common Stock Grant Aquire A 0.68 147,783 100.49K 147,783
19 Mar 20 Cocozza Nancy G Common Stock Grant Aquire A 0 66,218 0 129,506
19 Mar 20 Cocozza Nancy G Employee Stock Option Common Stock Grant Aquire A 0.68 115,148 78.3K 115,148
19 Mar 20 Schreiber David Common Stock Grant Aquire A 0 70,113 0 235,018
19 Mar 20 Palmieri Valerie Barber Employee Stock Option Common Stock Grant Aquire A 0.68 500,000 340K 500,000
14.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 29 30 -3.3%
Opened positions 6 7 -14.3%
Closed positions 7 4 +75.0%
Increased positions 6 6
Reduced positions 5 4 +25.0%
13F shares
Current Prev Q Change
Total value 11.63M 9.06M +28.4%
Total shares 14.36M 17.21M -16.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Oracle Investment Management 9.83M $7.96M 0.0%
Vanguard 2.23M $1.81M 0.0%
B. Riley Wealth Management 448.55K $363K +34.8%
MTB M&T Bank 300K $243K 0.0%
Alyeska Investment 280.06K $227K -44.0%
Geode Capital Management 239.05K $193K +8.4%
LNC Lincoln National 174.92K $142K 0.0%
BLK BlackRock 127.17K $103K +1.5%
Cannell Peter B & Co 117.2K $95K -59.0%
Ardsley Advisory Partners 88.08K $71K NEW
Largest transactions
Shares Bought/sold Change
Opaleye Management 0 -1.27M EXIT
Calamos Advisors 0 -796.11K EXIT
Perkins Capital Management 0 -336K EXIT
Russell Investments 0 -321.12K EXIT
Alyeska Investment 280.06K -220.16K -44.0%
Cannell Peter B & Co 117.2K -168.8K -59.0%
B. Riley Wealth Management 448.55K +115.7K +34.8%
Millennium Management 51.6K -93.28K -64.4%
Ardsley Advisory Partners 88.08K +88.08K NEW
Commonwealth Equity Services 51.78K +51.78K NEW

Financial report summary

?
Competition
Abbott Laboratories
Risks
  • If we are unable to increase the volume of OVA1 sales, our business, results of operations and financial condition will be adversely affected.
  • Failures by third-party payers to reimburse OVA1 or changes or variances in reimbursement rates could materially and adversely affect our business, financial condition and results of operations.
  • We will need to raise additional capital in the future, and if we are unable to secure adequate funds on terms acceptable to us, we may be unable to execute our business plan.
  • If we or our suppliers fail to comply with FDA requirements for production, marketing and post-market monitoring of our products, we may not be able to market our products and services and may be subject to stringent penalties, product restrictions or recall; further improvements to our manufacturing operations may be required that could entail additional costs.
  • If a third party infringes on our proprietary rights, we may lose any competitive advantage we may have as a result of diversion of our time, enforcement costs and the loss of the exclusivity of our proprietary rights.
  • If others successfully assert their proprietary rights against us, we may be precluded from making and selling our products or we may be required to obtain licenses to use their technology.
  • Future litigation against us could be costly and time consuming to defend.
  • Because our business is highly dependent on key executives and employees, our inability to recruit and retain these people could hinder our business plans.
  • Business interruptions could limit our ability to operate our business.
  • Changes in healthcare policy could increase our costs and impact sales of and reimbursement for our tests.
  • We are subject to environmental laws and potential exposure to environmental liabilities.
  • The operation of ASPiRA LABS requires us to comply with numerous laws and regulations, which is expensive and time-consuming and could adversely affect our business, financial condition and results of operations, and any failure to comply could result in exposure to substantial penalties and other harm to our business.
  • If we underprice our IVD contracts, overrun our IVD cost estimates or fail to receive approval for or experience delays in documentation of IVD change orders, it could adversely affect our business, financial condition and results of operations.
  • The operation of ASPiRA IVD and ASPiRA LABS depend on the effectiveness and availability of our information systems, including the information systems we use to provide services to our customers and to store employee data, and failures of these systems, including in connection with cyber-attacks, may materially limit our operations or have an adverse effect on our reputation.
  • The liquidity and trading volume of our common stock may be low, and our ownership is concentrated.
  • Anti-takeover provisions in our charter, bylaws, other agreements and under Delaware law could make a third-party acquisition of the Company difficult.
  • Because we do not intend to pay dividends, our stockholders will benefit from an investment in our common stock only if it appreciates in value.
  • We may need to sell additional shares of our common stock or other securities in the future to meet our capital requirements, which could cause significant dilution.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: aim, biopsy, conclusion, conducting, correctly, coupled, Coupling, decided, demonstrated, difficult, discontinue, doctor, driven, important, inventory, lowest, minimal, mission, mix, negotiating, percentage, Preoperative, Presurgical, refine, retirement, science, sector, serial, serially, specialist, stabilize, Surgical, Tackling, titled, Wait, Watch, wellbeing, wind
Removed: advancement, benign, cleared, European, fluctuate, half, innovative, largely, manage, million, reinvested, reorganized, stronger, vision, warrant